From the Blood Journals

From the Blood Journals

Research from the Blood family of journals: Blood and Blood Advances

WIB_icon

Asciminib Superior to Bosutinib in Chronic-Phase CML

Asciminib was more effective than bosutinib at improving the rate of a major molecular response in patients with chronic myeloid leukemia in chronic phase...

Early Catheter Removal Does Not Increase Risk of PE

Among patients with a hematologic malignancy and central venous catheter (CVC)–associated upper extremity deep vein thrombosis (UEDVT), removing CVCs within 48 hours of diagnosis...
WIB_icon

Flow Cytometry as a Prognostic Tool for Children With Down Syndrome and AML

The use of flow cytometry alone to determine measurable residual disease (MRD) status did not sufficiently identify children with acute myeloid leukemia (AML) and...
WIB_icon

Blunted Response to COVID-19 Vaccines in Transplant and Cellular Therapy Recipients

Many patients who undergo bone marrow transplant and CAR-T cell therapy do not mount a detectable humoral response to authorized COVID-19 vaccines, according to...

rFIXFc as Prophylaxis and Treatment in Pediatric Hemophilia B

Results from the phase III B-LONG study published in Blood Advances found that recombinant factor IX Fc fusion protein (rFIXFc) was an effective prophylactic...

Treatment Delays and Hemostatic Abnormalities Predict Death in Newly Diagnosed APL

Major factors associated with early deaths in hospitalized patients with newly diagnosed acute promyelocytic leukemia (APL) included treatment delays and the incidence of hemostatic...

Conserving Red Blood Cell Units in the Treatment of Patients With SCD During Blood...

The ongoing COVID-19 pandemic has led to severe blood shortages within the health care delivery system, disproportionately affecting the supply of red blood cells...

Oblimersen Shows No Added Benefit in Newly Diagnosed Acute Myeloid Leukemia

The addition of BCL-2 antisense oligonucleotide oblimersen to standard induction chemotherapy did not improve remission rates in older patients with newly diagnosed acute myeloid...

Polatuzumab as Bridging or Salvage Therapy for Patients With Relapsed/Refractory LBCL

Polatuzumab vedotin was approved in 2019 in combination with bendamustine and rituximab for patients with relapsed or refractory large B-cell lymphoma (LBCL). It showed...
WIB_icon

Belumosudil Induces Responses in Refractory Chronic Graft-Versus-Host Disease

Belumosudil, a selective Rho-associated coiled-coil–containing protein kinase-2 (ROCK2) inhibitor, was associated with organ responses in heavily pretreated patients with chronic graft-versus-host disease (cGVHD) that...
Advertisement

Current Issue

September 2021 Volume 7 Issue 11

This issue discusses fertility preservation for young patients with cancer, reviews treatment options for primary immune thrombocytopenia, and more.

Block title